Diffuse large B-cell lymphoma (DLBCL)
ADCTADC TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for ZYNLONTA (Loncastuximab Tesirine) + COLUMVI (glofitamab) in Diffuse large B-cell lymphoma (DLBCL). The expected timing is based on the latest available company guidance and may change.
LOTIS-7 trial. 4/4/24- DE study completed. Initiated enrollment in Part 2 dose expansion. 12/11/24- Reported initial data. 12/3/25– Updated combo efficacy data reported, enrollment completes H1 2026. Share full data at a medical mtg by YE 2026. 03/10/26:- LOTIS-7 December 2025 data: 89.8% ORR, 77.6% CR in 49 patients; full data by YE 2026. 05/04/26:- LOTIS-7 enrollment completion still expected H1 2026; full Phase 1b data by year-end 2026. 06/30/26:- LOTIS-7 enrollment complete (100 pts). Full Ph1b data expected Q4 2026; publication by YE 2026. 08/13/26:- LOTIS-7 enrollment completed in 100 patients. Full data will be presented later in 2026; BTD submission will occur this year.
Verification
Confirm timing and program details against the company announcement or filing.